Pathstone Holdings
PMVP icon

Pathstone Holdings’s PMV Pharmaceuticals PMVP Stock Holding History

Pathstone Holdings’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.4K Hold
17,487
– – ﹤0.01% 2321
2026
Q1 		$21.7K Hold
17,487
– – ﹤0.01% 2205
2025
Q4 		$21.9K Hold
17,487
– – ﹤0.01% 2209
2025
Q3 		$24.5K Hold
17,487
– – ﹤0.01% 2317
2025
Q2 		$18.5K Buy
+17,487
New +$17.2K ﹤0.01% 2171

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Pathstone Holdings's PMVP Position: Q2 2026 in Review

Pathstone Holdings held its PMV Pharmaceuticals (PMVP) position steady in Q2 2026 at 17,487 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2321.

Pathstone Holdings first reported a position in PMVP in Q2 2025 and has held it in 5 quarters since. The position peaked at $24.5K in Q3 2025. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Pathstone Holdings held 17,487 shares of PMV Pharmaceuticals worth $23.4K as of Q2 2026.
  • Pathstone Holdings left its PMV Pharmaceuticals share count unchanged in Q2 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2321 holding.
  • Pathstone Holdings first reported a position in PMV Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Pathstone Holdings's PMV Pharmaceuticals position peaked at $24.5K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.